Picture of Owlet logo

OWLT — Owlet News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousSmall CapNeutral

Owlet Q2 revenue beats analyst estimates on subscription growth

Owlet Q2 revenue beats analyst estimates on subscription growth


Overview

  • Smart infant monitoring firm's Q2 revenue rose 29.9%, beating analyst expectations

  • Adjusted EPS and adjusted EBITDA for Q2 both beat analyst expectations

  • Company attributed results to broad-based growth and expansion of subscription platform


Outlook

  • Owlet sees 2026 revenue between $118 mln and $122 mln, unchanged from prior guidance

  • Company raises 2026 gross margin outlook to 53%-55% from 50%-52%, citing one-time tariff refund

  • Owlet lifts 2026 adjusted EBITDA forecast to $10.75 mln-$12.75 mln on one-time refund benefit


Result Drivers

  • SUBSCRIPTION GROWTH - Co said increased revenue from Owlet360 subscription service was a key driver of higher gross margin and overall revenue

  • INTERNATIONAL MOMENTUM - Co cited standout international momentum as a contributor to topline growth

  • FAVORABLE PRODUCT MIX - Co said improved gross margin was partly due to favorable product mix and fixed cost absorption


Company press release: ID:nBwy0kZRa


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q2 Revenue

Beat

$33.90 mln

$31.71 mln (5 Analysts)

Q2 Adjusted EPS

Beat

$0.20

-$0.05 (3 Analysts)

Q2 Loss Per Share

$0.05

Q2 Adjusted EBITDA (Excluding Tariff Refund)

Beat

$2.90 mln

$2.15 mln (4 Analysts)

Q2 Gross Margin

64.40%

Q2 Operating Expenses

$20.10 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

  • Wall Street's median 12-month price target for Owlet Inc is $13.50, about 149.1% above its August 10 closing price of $5.42


Reuters Recommended Reads

  • Aug 10 - Life360 Q2 revenue rises 38%, beats analyst estimates

  • Aug 11 - Hims & Hers' shift to branded obesity drugs drives wider quarterly loss

  • Aug 10 - Tactile Systems Q2 revenue up 9%, slightly beats estimates


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Recent news on Owlet

See all news